Allyson Mateja
National Institutes of Health · 38 works · 575 citations · h-index 12
Top works
- Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis
- Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses
- Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms
- Elevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System
- Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
- Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial
- Reappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years
- Severe food allergy reactions are associated with α-tryptase
- The Structure of V-Antigen, an Essential Virulence Factor and Mediator of Immunity against Plague
- Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers
- Development of Inapparent Dengue Associated With Increased Antibody Levels to Aedes aegypti Salivary Proteins: A Longitudinal Dengue Cohort in Cambodia
- Xenodiagnosis to Search for Borrelia burgdorferi After Antibiotic Treatment of Lyme Disease: A Prospective Cohort Study
- The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death
- Comparison of clinical characteristics of Zika and dengue symptomatic infections and other acute illnesses of unidentified origin in Mexico
- Predictors of low bone density and fracture risk in Loeys–Dietz syndrome
- A unique immune signature of serum cytokine and chemokine dynamics in patients with Zika virus infection from a tropical region in Southern Mexico
- Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial
- Different Clinical Presentations of Human Rhinovirus Species Infection in Children and Adults in Mexico
- Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine
- Pediatric SARS-CoV-2 outcomes study (PECOS): 12-month longitudinal analysis of post-COVID symptoms in infected versus uninfected participants